## Lucentis (ranibizumab)
**Effective 01/01/2021**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Benefit</th>
<th>Program Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>☒ MassHealth</td>
<td>☐ Commercial/Exchange</td>
<td>☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy</td>
</tr>
<tr>
<td>☐</td>
<td>☐ Pharmacy Benefit</td>
<td></td>
</tr>
<tr>
<td>☒</td>
<td>☔ Medical Benefit (NLX)</td>
<td></td>
</tr>
</tbody>
</table>

### Specialty Limitations
This medication has been designated specialty and must be filled at a contracted specialty pharmacy.

### Contact Information

<table>
<thead>
<tr>
<th>Specialty Medications</th>
<th>Non-Specialty Medications</th>
<th>Medical Specialty Medications (NLX)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Plans</td>
<td>MassHealth</td>
<td>All Plans</td>
</tr>
<tr>
<td>Phone: 866-814-5506</td>
<td>Phone: 877-433-7643</td>
<td>Phone: 844-345-2803</td>
</tr>
<tr>
<td>Fax: 866-249-6155</td>
<td>Fax: 866-255-7569</td>
<td>Fax: 844-851-0882</td>
</tr>
</tbody>
</table>

### Exceptions
N/A

### Overview
Ranibizumab is a recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.

### Coverage Guidelines

#### Diabetic Macular Edema
Authorization of 24 months may be granted for treatment of diabetic macular edema.

#### Neovascular (Wet) Age-Related Macular Degeneration
Authorization of 24 months may be granted for treatment of neovascular (wet) age-related macular degeneration.

#### Macular Edema Following Retinal Vein Occlusion
Authorization of 24 months may be granted for treatment of macular edema following retinal vein occlusion.

#### Diabetic Retinopathy
Authorization of 24 months may be granted for treatment of diabetic retinopathy.

#### Myopic Choroidal Neovascularization
Authorization of 24 months may be granted for treatment of myopic choroidal neovascularization.
Continuation of Therapy
All members requesting authorization for continuation of therapy must meet all initial authorization criteria.

Limitations
Initial approvals for all diagnoses will be granted for 24 months.

References

Review History
11/18/2020 – Transitioned from SGM to Custom Criteria; separated out MH vs. Comm/Exch

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.